echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Stroke: Sphingosine-1-phosphate (S1P) in the blood is closely related to the prognosis of cerebral ischemia

    Stroke: Sphingosine-1-phosphate (S1P) in the blood is closely related to the prognosis of cerebral ischemia

    • Last Update: 2021-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Sphingosine-1-phosphate (S1P) regulates cell survival, lymphocyte migration and endothelial barrier function-all of these processes are affected in acute ischemic stroke
    .


    Therefore, different S1P receptor agonists have been studied in many experimental stroke models and proved to be beneficial


    Therefore, different S1P receptor agonists have been studied in many experimental stroke models and proved to be beneficial


    Blood vessel

    Clinical trials using fingolimod together with alteplase have shown that fingolimod may reduce reperfusion injury and improve the clinical prognosis of patients with acute ischemic stroke
    .


    In addition to cerebrovascular diseases, in a nested case-control study, low S1P levels were associated with acute coronary syndrome and myocardial infarction


    Despite these previous studies, the relationship between S1P levels and clinical and outcome parameters in patients with acute stroke has not been studied yet
    .

    However, the relationship between S1P levels and clinical and outcome parameters in patients with acute stroke has not been studied

    In this way, Edzard Schwedhel and others at the University of Hamburg, Germany, explored the potential connection between S1P and clinical parameters and outcomes after acute ischemic stroke
    .

    In a prospective stroke cohort (MARK-STROKE), 374 patients with acute ischemic stroke or transient ischemic attack were enrolled (mean age: 67.
    9±13.
    0 years, gender: 64.
    7% were males).
    Mass spectrometry analysis of serum S1P on admission
    .

    Stroke

    In addition to the cross-sectional analysis, 79 adverse events (death, stroke, myocardial infarction, rehospitalization) were recorded in 270 patients during the follow-up period
    .


    Regression analysis adjusted for age, gender, low-density lipoprotein cholesterol, and vascular risk factors


    cholesterol

    In serum, low S1P was associated with a higher NIHSS score at admission and non-lacunnar infarcts in the anterior circulation determined by multivariate regression analysis
    .

    During the 294±170 days of follow-up, patients with S1P in the lowest tertile (<1.
    33 µmol/L) had more adverse events (Kaplan-Meier analysis, P=0.
    048 trend)
    .

    In the adjusted Cox regression analysis, the lowest tertile of S1P was associated with poorer outcomes after stroke (hazard ratio, HR 0.
    51 [95% confidence interval 0.
    28-0.
    92])
    .

    These results were confirmed in a separate cohort that low S1P levels were associated with higher NIHSS, larger infarct volume, and poorer results after 90 days
    .

    This Ge study implies: the harmful effects of low S1P levels in acute stroke, thus supporting the therapeutic potential of S1P mimics
    .

    The detrimental effects of low S1P levels in acute stroke thus support the therapeutic potential of S1P mimics
    .



    Original source:
    Schwedhelm E, Schwieren L, Tiedt S, et al.


    Serum Sphingosine-1-Phosphate Levels Are Associated With Severity and Outcome in Patients With Cerebral Ischemia .
    Stroke.


    Serum Sphingosine-1-Phosphate Levels Are Associated With Severity and Outcome in Patients With Cerebral Ischemia in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.